<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02599129</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 15-0549</org_study_id>
    <nct_id>NCT02599129</nct_id>
  </id_info>
  <brief_title>A Study of Secukinumab for the Treatment of Alopecia Areata</brief_title>
  <official_title>An Exploratory Study to Evaluate the Safety and Efficacy of Secukinumab in the Treatment of Extensive Alopecia Areata</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alopecia areata is a medical condition, in which the hair falls out in patches. The hair can
      fall out on the scalp or elsewhere on the face and body.

      Alopecia areata is an autoimmune skin disease, which means that the immune system is
      recognizing the hair follicles as foreign and attacking them, causing round patches of hair
      loss. It can progress to total scalp hair loss (alopecia totalis) or complete body hair loss
      (alopecia universalis). The scalp is the most commonly affected area, but the beard or any
      hair-bearing site can be affected alone or together with the scalp. Alopecia areata occurs in
      males and females of all ages, and is a highly unpredictable condition that tends to recur.
      Alopecia areata can cause significant distress to both patients and their families.

      Aim: To assess the effects of a new treatment called secukinumab in patients with alopecia
      areata. A total of 30 patients will be included in the study, which will run for a total of
      28 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low enrollment
  </why_stopped>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Achieving Severity of Alopecia Tool (SALT) Score of 50</measure>
    <time_frame>Week 24</time_frame>
    <description>Number of subjects achieving a Severity of Alopecia Tool (SALT) score of 50 at Week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving a SALT Score of 90 at Week 24</measure>
    <time_frame>week 24</time_frame>
    <description>Number of subjects achieving a SALT score of 90 at week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving a SALT Score of 90 at Week 28</measure>
    <time_frame>week 28</time_frame>
    <description>Number of subjects achieving a SALT score of 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Acheiving Physician's Global Assessment (PGA) Score of 3 or Above</measure>
    <time_frame>Week 24</time_frame>
    <description>Number of subjects achieving a Physician's Global Assessment (PGA) score of 3 or above at week 24 (0, no regrowth; 1, &lt;25% of regrowth; 2, 25%-49% of regrowth; 3, 50%-74% of regrowth; 4, 75%-99% of re- growth; 5, 100% of regrowth).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Dermatology Life Quality Index (DLQI) of 3 or Above</measure>
    <time_frame>Week 24</time_frame>
    <description>Number of subjects achieving a DLQI (Dermatology Life Quality Index), patient global assessment score of 3 or above at week 24 (0, no regrowth; 1, &lt;25% of regrowth; 2, 25%-49% of regrowth; 3, 50%-74% of regrowth; 4, 75%-99% of re- growth; 5, 100% of regrowth).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Alopecia Areata</condition>
  <arm_group>
    <arm_group_label>Secukinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg subcutaneous injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo subcutaneous injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secukinumab</intervention_name>
    <description>subcutaneous secukinumab (300 mg) at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including Week 20.</description>
    <arm_group_label>Secukinumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>ï¿¼subcutaneous placebo at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including week 20.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subject at least 18 years of age

          -  If female, the subject is not pregnant or nursing

          -  Subject is able to provide written informed consent and comply with the requirements
             of this study protocol.

          -  Subjects who are women of childbearing potential must have a negative urine pregnancy
             test at screening and must be practicing an adequate, medically acceptable method of
             birth control for at least 30 days before Day 0 and at least 6 months after the last
             study drug administration. Acceptable methods of birth control include intrauterine
             device (IUD); oral, transdermal, implanted or injected hormonal contraceptives (must
             have been initiated at least 1 month before entering the study); tubal ligation;
             abstinence and barrier methods with spermicide. Otherwise, if not of childbearing
             potential, subjects must: have a sterile or vasectomized partner; have had a
             hysterectomy, a bilateral oophorectomy or be clinically diagnosed infertile; or be in
             a menopausal state for at least a year.

          -  Subject with AA (unequivocal cases of AA), affecting at least 60% of the scalp, and
             present for at least 6 months.

          -  Tuberculin purified protein derivative (PPD) or QuantiFERON TB-Gold test (QFT)
             negative at the time of screening, or if patient has a history of positive PPD or
             QuantiFERON, he/she has completed the appropriate prophylaxis.

          -  Subject is judged to be in good general health as determined by the principal
             investigator based upon the results of medical history, laboratory profile, and
             physical examination.

        Exclusion Criteria:

          -  Other concomitant types of alopecia (androgenetic, female pattern, traction, scarring
             and others)

          -  Any subject who is pregnant or refuses to practice an acceptable method of birth
             control (as stated in inclusion criterion # 4)

          -  History of an ongoing, chronic or recurrent infectious disease, or evidence of
             tuberculosis infection as defined by a positive tuberculin purified protein derivative
             (PPD) or QuantiFERON TB-Gold test (QFT) at screening. Subjects with a positive or
             indeterminate PPD or QFT test may participate in the study if a full tuberculosis work
             up (according to local practice/guidelines) is completed within 12 weeks prior to
             randomization and establishes conclusively that the subject has no evidence of active
             tuberculosis. If presence of latent tuberculosis is established, then treatment must
             have been initiated at least for 4 weeks prior to randomization and the course of
             prophylaxis is planned to be completed.

          -  Active Crohn's disease

          -  Known hypersensitivity to latex

          -  Subjects with a history of HIV, or history of positive HCV or HBV

          -  Previous exposure to Secukinumab or other drug targeting IL-17A or its receptor; use
             of sensitizing therapy for alopecia areata including DPCP, squaric acid, DNCB within 1
             month; PUVA, or any form of phototherapy within 1 month; use of any immunosuppressive
             therapies (systemic corticosteroids, methotrexate, azathioprine, mycophenolate
             mofetil, cyclosporine) within 1 month; or use of topical therapies (two weeks). All
             the above therapies will not be allowed during this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Lebwohl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2015</study_first_submitted>
  <study_first_submitted_qc>November 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2015</study_first_posted>
  <results_first_submitted>November 2, 2017</results_first_submitted>
  <results_first_submitted_qc>November 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 30, 2017</results_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Mark Lebwohl</investigator_full_name>
    <investigator_title>Professor and System Chair, Dermatology</investigator_title>
  </responsible_party>
  <keyword>Alopecia areata</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled from November 2015 to March 2016.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Secukinumab</title>
          <description>Secukinumab: subcutaneous secukinumab (300 mg) at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including Week 20.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: subcutaneous placebo at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including week 20.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Secukinumab</title>
          <description>Secukinumab: subcutaneous secukinumab (300 mg) at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including Week 20.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: subcutaneous placebo at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including week 20.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.9" spread="14.3"/>
                    <measurement group_id="B2" value="52.2" spread="11.3"/>
                    <measurement group_id="B3" value="39.3" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Severity of Alopecial Tool (SALT) Score</title>
          <description>Scalp is divided into 4 areas namely, Vertex - 40% (0.4) of scalp surface area; right profile of scalp - 18% (0.18) of scalp surface area; left profile of scalp - 18% (0.18) of scalp surface area; Posterior aspect of scalp - 24% (0.24) of scalp surface area. Percentage of hair loss in any of these areas is percentage hair loss multiplied by percent surface area of the scalp in that area. SALT score is the sum of percentage of hair loss in all above mentioned areas.</description>
          <units>percent hair loss</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>SALT Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.5" spread="19.3"/>
                    <measurement group_id="B2" value="95.3" spread="7.9"/>
                    <measurement group_id="B3" value="87.1" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left profile of scalp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.6" spread="16.5"/>
                    <measurement group_id="B2" value="95.0" spread="10.0"/>
                    <measurement group_id="B3" value="87.7" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right profile of scalp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87.9" spread="12.9"/>
                    <measurement group_id="B2" value="95.0" spread="10.0"/>
                    <measurement group_id="B3" value="90.5" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posterior profile of scalp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84.3" spread="22.1"/>
                    <measurement group_id="B2" value="90.0" spread="14.1"/>
                    <measurement group_id="B3" value="86.4" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vertex (Top) profile of scalp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.4" spread="27.2"/>
                    <measurement group_id="B2" value="98.75" spread="2.5"/>
                    <measurement group_id="B3" value="85.8" spread="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Achieving Severity of Alopecia Tool (SALT) Score of 50</title>
        <description>Number of subjects achieving a Severity of Alopecia Tool (SALT) score of 50 at Week 24</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>Secukinumab: subcutaneous secukinumab (300 mg) at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including Week 20.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: subcutaneous placebo at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including week 20.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving Severity of Alopecia Tool (SALT) Score of 50</title>
          <description>Number of subjects achieving a Severity of Alopecia Tool (SALT) score of 50 at Week 24</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving a SALT Score of 90 at Week 24</title>
        <description>Number of subjects achieving a SALT score of 90 at week 24</description>
        <time_frame>week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>Secukinumab: subcutaneous secukinumab (300 mg) at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including Week 20.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: subcutaneous placebo at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including week 20.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving a SALT Score of 90 at Week 24</title>
          <description>Number of subjects achieving a SALT score of 90 at week 24</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving a SALT Score of 90 at Week 28</title>
        <description>Number of subjects achieving a SALT score of 90</description>
        <time_frame>week 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>Secukinumab: subcutaneous secukinumab (300 mg) at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including Week 20.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: subcutaneous placebo at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including week 20.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving a SALT Score of 90 at Week 28</title>
          <description>Number of subjects achieving a SALT score of 90</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Acheiving Physicianâs Global Assessment (PGA) Score of 3 or Above</title>
        <description>Number of subjects achieving a Physicianâs Global Assessment (PGA) score of 3 or above at week 24 (0, no regrowth; 1, &lt;25% of regrowth; 2, 25%-49% of regrowth; 3, 50%-74% of regrowth; 4, 75%-99% of re- growth; 5, 100% of regrowth).</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>Secukinumab: subcutaneous secukinumab (300 mg) at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including Week 20.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: subcutaneous placebo at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including week 20.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Acheiving Physicianâs Global Assessment (PGA) Score of 3 or Above</title>
          <description>Number of subjects achieving a Physicianâs Global Assessment (PGA) score of 3 or above at week 24 (0, no regrowth; 1, &lt;25% of regrowth; 2, 25%-49% of regrowth; 3, 50%-74% of regrowth; 4, 75%-99% of re- growth; 5, 100% of regrowth).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Dermatology Life Quality Index (DLQI) of 3 or Above</title>
        <description>Number of subjects achieving a DLQI (Dermatology Life Quality Index), patient global assessment score of 3 or above at week 24 (0, no regrowth; 1, &lt;25% of regrowth; 2, 25%-49% of regrowth; 3, 50%-74% of regrowth; 4, 75%-99% of re- growth; 5, 100% of regrowth).</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>Secukinumab: subcutaneous secukinumab (300 mg) at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including Week 20.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: subcutaneous placebo at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including week 20.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Dermatology Life Quality Index (DLQI) of 3 or Above</title>
          <description>Number of subjects achieving a DLQI (Dermatology Life Quality Index), patient global assessment score of 3 or above at week 24 (0, no regrowth; 1, &lt;25% of regrowth; 2, 25%-49% of regrowth; 3, 50%-74% of regrowth; 4, 75%-99% of re- growth; 5, 100% of regrowth).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Secukinumab</title>
          <description>Secukinumab: subcutaneous secukinumab (300 mg) at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including Week 20.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: subcutaneous placebo at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including week 20.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Plaque Psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Wisdom Tooth Extraction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mark Lebwohl</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>2122413288</phone>
      <email>giselle.singer@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

